leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 00:49:20 - browse：822

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

WSS

The Sacklers, horror, and ‘The Fall of the House of Usher’

FDA approves potent Eli Lilly obesity drug, Zepbound

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Study: New antibiotic targets gonorrhea as well as last existing drug

Medtronic CEO on promising devices for diabetes, hypertension

WHO may add ‘noma' to its list of neglected tropical diseases

leisure time

leisure time

Gilead needs Arcellx more than ever

leisure time

Medical leaders decry Supreme Court decision on affirmative action

More doctors should go into startup world

Activists slam private health insurers over coverage restrictions

The Sacklers, horror, and ‘The Fall of the House of Usher’

The high cost of giving birth even with insurance

Removing probiotics from the NICU could threaten preemies' health

Guidelines to prevent youth baseball injuries need more muscle

CDC recommends rationing of RSV shot due to shortages

In age of alternative facts, a scholarly course on calling out crap

STAT Executive Editor Rick Berke on STAT's 8th birthday

focus

Telehealth options flood the market as retailers push virtual care

Eli Lilly to pay $200M for Beam’s stake in gene

The new shift in health care is toward less care

Removing probiotics from the NICU could threaten preemies' health

Eli Lilly to pay $200M for Beam’s stake in gene

Extreme heat events are a public health emergency

focus

entertainment

entertainment

knowledge